Anticancer bispecific antibody R&D advances: a study focusing on research trend worldwide and in China

被引：13

作者：

Zhang, Zhonghan ^{[1
]}

Luo, Fan ^{[1
]}

Cao, Jiaxin ^{[1
]}

Lu, Feiteng ^{[1
]}

Zhang, Yang ^{[2
]}

Ma, Yuxiang ^{[2
]}

Zeng, Kangmei ^{[1
]}

Zhang, Li ^{[1
]}

Zhao, Hongyun ^{[1
,2
]}

机构：

[1] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Dept Med Oncol,Canc Ctr, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China

[2] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Dept Clin Res,Canc Ctr, Guangzhou, Peoples R China

来源：

JOURNAL OF HEMATOLOGY & ONCOLOGY | 2021年 / 14卷 / 01期

基金：

中国国家自然科学基金;

关键词：

Bispecific antibody; BsAbs; China; Worldwide; Clinical trials;

D O I：

10.1186/s13045-021-01126-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: The bispecific antibody (bsAbs) research around the world has undergone great changes. We analyzed the global trend of bsAbs research and compared the differences in clinical research of bsAbs between China and worldwide. Methods: BsAbs research clinical trials information was retrieved through the online open-resource clinical trial registration platform. Research information including organizations, identity numbers, locations, phases, participating centers, conditions, status, enrollment, targets, spectrums of mechanism of action (MOA), and start date was collected. Clinical trials were divided into two categories based on the attributes of pharmaceutical companies (international or China-initiated or involved). Results: From 1997 to 2020, 272 clinical trials regarding bsAbs research were retrieved. Twenty-nine percent of the studies were contributed by companies from Chinese institutions, which followed the USA and ranked second. The clinical trials of bsAbs are mainly concentrated on phase I (n = 161), phase I/II (n = 54), and phase II (n = 51), and the number of phase III trials is still rare (n = 4). Tumor species distribution analysis shows that there are significantly higher focuses on gastric cancer (n = 18), esophageal/gastroeso phageal junction cancer (n = 16), bladder cancer (n = 10), biliary malignant tumor (n = 8), nasopharyngeal cancer (n = 6), and thymic cancer (n = 2) in China. BsAbs target and spectrums of MOA analysis showed that international companies mainly focus on bsAbs with CD3-based (n = 63) target with MOA of T-cell redirection, while researches in China pay more attention to PD-1 (n = 9)/PD-L1 (n = 7) axises with MOA of double immune checkpoint blocking. Conclusion: Global bsAbs research increased rapidly during the 1997 to 2020 period. The developed countries in America and Europe are leading the trend of bsAbs research. Anticancer bsAbs clinical research in China is booming and chasing after the world trend.

引用

页数：5

共 12 条

[1] China Food and Drug Administration, 2016, NOT GEN ADM PEOPL RE
[2] China Food and Drug Administration, 2017, DEC ADJ REG IMP REG
[3] China Food and Drug Administration, 2017, POL REF CLIN TRIAL A
[4] China Food and Drug Administration, 2017, OP STAT COUNC REG DE
[5] China Food and Drug Administration, 2017, POL ACC REV APPR NEW
[6] Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies
Husain, Bushra
Ellerman, Diego
[J]. BIODRUGS, 2018, 32 (05) : 441 - 464
[7] Bispecific antibodies for cancer therapy: A review
Krishnamurthy, Anuradha
Jimeno, Antonio
[J]. PHARMACOLOGY & THERAPEUTICS, 2018, 185 : 122 - 134
[8] Bispecific antibodies: a mechanistic review of the pipeline
Labrijn, Aran F.
Janmaat, Maarten L.
Reichert, Janice M.
Parren, Paul W. H. I.
[J]. NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (08) : 585 - 608
[9] A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
Suurs, Frans V.
Lub-de Hooge, Marjolijn N.
de Vries, Elisabeth G. E.
de Groot, Derk Jan A.
[J]. PHARMACOLOGY & THERAPEUTICS, 2019, 201 : 103 - 119
[10] Zhang Jing, 2020, Antib Ther, V3, P126, DOI 10.1093/abt/tbaa011

← 1 2 →